Hair loss remains an area lacking biotechnology innovation. The drugs currently available are older products offering limited efficacy. Some of them cannot be used by women. Veradermics aims to shake up this market with a new twist on an old drug for pattern baldness. The biopharmaceutical company now has $256 million in IPO cash to finance late-stage clinical trials that, if successful, could support an FDA submission.Veradermics was able to raise more than planned. In preliminary financial ter...
Continue Reading
Sign up for FREE to read the full article and access 143K+ alternative investment headlines.
Alternative Investment News